Servier and MaSTherCell SA, a CDMO specializing in the delivery of optimized process industrialization capacities to cell therapy organizations, have signed a master service agreement for the development of a manufacturing platform for allogeneic cell therapies. 
 
Under the agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing platform, which will enable industrial and commercial manufacturing of Servier cell therapy products. This is a critical step in development of these products for later stage clinical trials. 
 
Cell therapies have shown promising results in treating cancers. However so far, successful development has been mainly limited to autologous therapies. This approach, where the patient’s cells are collected then used to create a drug for that specific patient, is limited by the lack of possibility of industrialized manufacturing, thus restricting its access to few patients. Allogeneic therapies, or off-the-shelf treatments, potentially offer the technology to a higher number of patients, however manufacturing and scale-up remains a challenge. 
 
Servier is developing UCART-19 with two clinical trials in relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL), in pediatric and adults patients. MaSTherCell anticipates that it will complete the development of the initial CAR-T platform in 2018. This will then be an efficient complement to the bioproduction facilities that Servier is developing at its site at Gidy (France), which will mainly focus on the production of antibodies. 
 
“This partnership will result in developing solutions for one of the biggest challenges to the ongoing development of the cell therapy sector. MaSTherCell has quickly built the most extensive CDMO experience in manufacturing and process industrialization development in the cell therapy industry,” said Denis Bedoret, CBO at MaSTherCell. “This enables MaSTherCell to leverage that experience to deliver solutions to contribute to the Servier cell therapy pipeline. We will thus be able to directly contribute to delivery of life-saving cell therapy treatment to patients.”
 
“The scale up of manufacturing for late scale clinical trials still remains one of the biggest industry-wide challenges in the cell therapy sector, and especially in a CAR-T field still in its infancy,” said Marielle Anger-Leroy, director of Biotechnology Industrial Development at Servier. “Being pioneers with these innovative therapies means that we have to find the best partners to maximize the chances of delivering these therapies to patients with few alternative options.”